CVS Health Corporation $CVS is Sector Gamma AS’s 10th Largest Position

25 Jan 2026, 12:26 by Kim Johansen · The Markets Daily

Sector Gamma AS reduced its stake in CVS Health Corporation (NYSE:CVS – Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 156,202 shares of the pharmacy operator’s stock after selling 6,798 shares during the period. CVS Health makes up approximately 2.9% of Sector Gamma AS’s portfolio, making the stock its 10th biggest position. Sector Gamma AS’s holdings in CVS Health were worth $11,776,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Harbor Capital Advisors Inc. lifted its holdings in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares during the last quarter. Avion Wealth raised its position in CVS Health by 99.0% in the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 189 shares during the period. Corundum Trust Company INC acquired a new position in CVS Health during the third quarter worth $29,000. Harbor Asset Planning Inc. purchased a new position in shares of CVS Health during the second quarter worth $30,000. Finally, Front Row Advisors LLC grew its stake in shares of CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after buying an additional 371 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: CVS is activating pharmacies and advising patients to pick up prescriptions ahead of a major winter storm — shows operational readiness and continuity of care that can limit service disruption and protect short‑term revenue. Read More.
Positive Sentiment: CVS announced programs aimed at making health insurance “simpler and more affordable,” signaling potential member growth and pricing or mix improvements for its health-insurance businesses. Read More.
Positive Sentiment: Operational/PBM changes: CVS said it will cut some prior‑authorization requirements and expand rebate‑sharing — moves that could reduce friction for care delivery, improve customer experience and blunt policy/competitive criticisms. Read More.
Positive Sentiment: Strategic/innovation: CVS is partnering with the University of Maryland on AI and pharmacy workforce development — a long‑term positive for efficiency and talent pipeline in its retail and clinical operations. Read More.
Positive Sentiment: Market positioning: Reports show heavy buying of CVS call options, indicating some investors are positioned for further upside in the near term. Read More.
Neutral Sentiment: Legal outcome: A Bloomberg Law piece says CVS and UnitedHealth successfully defended against an antitrust suit over drug costs — a favorable legal development but not necessarily dispositive for broader PBM scrutiny. Read More.
Negative Sentiment: House Judiciary Committee report accuses CVS/Caremark of thwarting competition and targeting independent pharmacies — the committee alleges anticompetitive PBM practices, escalating regulatory and litigation risk that could pressure margins and valuation. Read More.
Negative Sentiment: Follow‑up coverage: Multiple outlets (Becker’s, Seeking Alpha, MSN) detail the committee’s findings and show CVS executives were scrutinized in hearings over high costs and PBM conduct — these stories amplify political and regulatory uncertainty that investors price as risk. Read More. Read More. Read More.

CVS Health Stock Up 0.4%

Shares of CVS Health stock opened at $83.02 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. CVS Health Corporation has a 52-week low of $53.28 and a 52-week high of $85.15. The company has a market capitalization of $105.39 billion, a P/E ratio of 218.49, a P/E/G ratio of 0.76 and a beta of 0.48. The company has a 50 day moving average of $79.05 and a 200 day moving average of $74.78.

CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. The company had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Thursday, January 22nd. CVS Health’s payout ratio is 700.00%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CVS shares. Jefferies Financial Group raised their target price on CVS Health from $92.00 to $98.00 in a report on Thursday, October 30th. Wolfe Research increased their price target on shares of CVS Health from $85.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Raymond James Financial increased their target price on shares of CVS Health from $75.00 to $90.00 in a report on Friday, October 31st. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of CVS Health in a research note on Thursday, December 4th. Nineteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $94.86.

Read Our Latest Stock Analysis on CVS Health

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.